Rachel Fuelling
Physician Assistant · Raleigh, NCNPI 1871182139
Payments from drug & device makers
Across 353 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$853
- AbbVie$610
- Lilly USA, LLC$579
- Bayer$293
- GSK$285
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,920100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $1,142 |
| AstraZeneca(2 entities) | 44 | $853 |
| AbbVie | 35 | $610 |
| Lilly USA, LLC | 30 | $579 |
| Bayer | 19 | $293 |
| GSK | 17 | $285 |
| Pfizer | 16 | $254 |
| Merck | 16 | $250 |
| Boehringer Ingelheim | 13 | $206 |
| Idorsia Pharmaceuticals US Inc | 8 | $141 |
| Hikma Pharmaceuticals USA | 7 | $127 |
| Exact Sciences | 7 | $124 |
| Amgen | 7 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $116 |
| Shield Therapeutics Inc | 2 | $96 |
| Grifols USA, LLC | 4 | $90 |
| Amarin Pharma, Inc. | 5 | $86 |
| Corium, LLC | 3 | $68 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Eisai Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| Astellas Pharma US Inc | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Lifescan, Inc. | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Viiv Healthcare Company | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Cequr Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$109
How this compares
$5,920 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 269 | $339,236 |
| FarxigaDapagliflozin Propanediol | 143 | $151,160 |
| EliquisApixaban | 124 | $117,645 |
| JardianceEmpagliflozin | 73 | $86,088 |
| MounjaroTirzepatide | 66 | $78,520 |
| RybelsusSemaglutide | 37 | $66,208 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $38,897 |
| TrulicityDulaglutide | 28 | $35,147 |
| Repatha SureclickEvolocumab | 42 | $31,183 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $25,843 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $25,717 |
| KerendiaFinerenone | 12 | $20,704 |
| JanuviaSitagliptin Phosphate | 11 | $19,129 |
| LinzessLinaclotide | 16 | $13,735 |
| MyrbetriqMirabegron | 19 | $13,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,142 | $405,444306 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $853 | $182,946202 claims |
| PfizerEliquis | $254 | $117,645124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $579 | $113,66794 claims |
| Boehringer IngelheimJardiance | $206 | $86,08873 claims |
| GSKTrelegy Ellipta | $285 | $38,89751 claims |
| MerckJanuvia, Belsomra | $250 | $29,28828 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $39 | $25,71735 claims |
| BayerKerendia | $293 | $20,70412 claims |
| AbbVieLinzess, Synthroid | $610 | $16,00339 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $13,29019 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $2,206238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Raleigh
- Jessica CainRaleigh$77K
- Carrie McGroartyRaleigh$69K
- Jaime BullRaleigh$25K
- Kristina KohuthRaleigh$24K
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.